First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA

Loading...
Loading...
Halozyme Therapeutics, Inc.
HALO
today announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck's KEYTRUDA (pembrolizumab) in a clinical trial to determine the maximum tolerated dose of PEGPH20 and antitumor activity of the combined therapies. The Halozyme sponsored Phase 1b study is being conducted at a number of leading sites in the U.S., and is evaluating patients with advanced non-small cell lung and gastric cancers. Following an initial dose escalation portion to determine the maximum tolerated dose of PEGPH20 in combination with KEYTRUDA, the study will be expanded to determine antitumor activity including overall response rate, duration of response and progression-free survival in patients with high levels of hyaluronan (HA). HA is a glycosaminoglycan, or chain of natural sugars in the body that can accumulate around cancer cells creating high pressure in a tumor, constricting blood flow and thereby reducing access of chemotherapy and immunotherapeutic agents, like KEYTRUDA. PEGPH20 degrades HA, reducing tumor pressure and increasing blood flow to treat the tumor. During the expansion portion, the study seeks to enroll approximately 50 patients with high HA tumors who have relapsed or refractory stage IIIB/IV non-small cell lung cancer treated with at least one platinum-based regimen, or who have recurrent locally advanced/metastatic gastric adenocarcinoma who are also PDL-1 positive and have failed at least one chemotherapy regimen. "Our goal is to make a difference in the lives of patients, and that starts by studying the safety, tolerability and efficacy of PEGPH20 in a broad range of tumor types and in combination with a broad range of therapeutic agents," said Dr. Helen Torley, president and CEO of Halozyme. "With this study, we see an opportunity to expand the potential benefits of immunotherapy through the novel combination of KEYTRUDA and PEGPH20, targeting two of the most difficult to treat cancers." For information on Keytruda, please go to keytruda.com.
Loading...
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...